Acquisitions and Divestitures - Narrative (Zymergen) (Details) - USD ($) $ in Thousands		12 Months Ended
	Oct. 19, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Feb. 26, 2021
Business Acquisition [Line Items]
Severance cost			$ 11,100
Increase to accounts receivable		$ (50,068)	(55,024)	$ 114,094
Retention amount			7,400
Net loss		(892,869)	(2,106,372)	(1,836,642)
General and administrative		$ 385,025	$ 1,429,799	$ 862,952
Commo stock, issued (in shares)		2,138,993,000	2,031,884,000
New Ginkgo Common Stock
Business Acquisition [Line Items]
General and administrative			$ 11,900
Commo stock, issued (in shares)			300,000
Common Class A
Business Acquisition [Line Items]
Class of warrant or right, number of securities called by rights (in shares)					1
Commo stock, issued (in shares)		1,639,885,000	1,448,235,000
Zymergen
Business Acquisition [Line Items]
Severance cost	$ (6,152)
Goodwill, period increase (decrease)	2,200
Increase to accounts receivable	1,800
Decrease in other current liabilities	$ 400
Revenue			$ 2,200
Net loss			26,000
Commo stock, issued (in shares)	96,900,000
Equity issuance costs			$ 1,700
Zymergen | Common Class A
Business Acquisition [Line Items]
Class of warrant or right, number of securities called by rights (in shares)	0.9179
Commo stock, issued (in shares)	99,400,000